- Home
- YETI vs JANX Comparison
YETI vs JANX Comparison
Compare YETI & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YETI
- JANX
- Stock Information
- Founded
- YETI 2006
- JANX 2017
- Country
- YETI United States
- JANX United States
- Employees
- YETI N/A
- JANX N/A
- Industry
- YETI Recreational Games/Products/Toys
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- YETI Consumer Discretionary
- JANX Health Care
- Exchange
- YETI Nasdaq
- JANX Nasdaq
- Market Cap
- YETI 2.5B
- JANX 1.4B
- IPO Year
- YETI 2018
- JANX 2021
- Fundamental
- Price
- YETI $32.75
- JANX $24.88
- Analyst Decision
- YETI Buy
- JANX Strong Buy
- Analyst Count
- YETI 15
- JANX 7
- Target Price
- YETI $39.79
- JANX $94.29
- AVG Volume (30 Days)
- YETI 2.0M
- JANX 658.5K
- Earning Date
- YETI 08-07-2025
- JANX 08-06-2025
- Dividend Yield
- YETI N/A
- JANX N/A
- EPS Growth
- YETI 4.22
- JANX N/A
- EPS
- YETI 2.08
- JANX N/A
- Revenue
- YETI $1,839,607,000.00
- JANX $9,336,000.00
- Revenue This Year
- YETI $4.93
- JANX N/A
- Revenue Next Year
- YETI $5.47
- JANX $1,470.82
- P/E Ratio
- YETI $15.72
- JANX N/A
- Revenue Growth
- YETI 8.38
- JANX 28.12
- 52 Week Low
- YETI $26.61
- JANX $22.48
- 52 Week High
- YETI $45.25
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- YETI 61.40
- JANX 50.75
- Support Level
- YETI $29.81
- JANX $22.74
- Resistance Level
- YETI $33.60
- JANX $24.73
- Average True Range (ATR)
- YETI 1.05
- JANX 1.25
- MACD
- YETI 0.29
- JANX 0.16
- Stochastic Oscillator
- YETI 85.27
- JANX 60.44
About YETI YETI Holdings Inc.
YETI Holdings Inc is a designer, marketer, and distributor of premium products for the outdoor and recreation market sold under the YETI brand. The company offers products including coolers and equipment, drinkware, and other accessories. Its trademark products include YETI Tundra, Hopper, YETI TANK, Rambler, Colster, Rambler among others. The company distributes products through wholesale channels and through direct-to-consumer, or DTC, channels.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.